BiotechTube
Home/Beactica Therapeutics/Per Källblad, Ph.D.
PK

Per Källblad, Ph.D.

Chief Executive Officer & Co-founder

Beactica Therapeutics

Therapeutic Areas

Oncology

Beactica Therapeutics Pipeline

DrugIndicationPhase
BEA-17GlioblastomaPre-clinical
YAP-TEAD ProgrammeCancers (Hippo pathway dysregulation)Pre-clinical
ZFTA-KLHL20 ProgrammeCancers with ZFTA fusions (e.g., ependymoma)Discovery/Pre-clinical